Amylyx Pharmaceuticals (AMLX) Common Equity (2021 - 2026)

Amylyx Pharmaceuticals' Common Equity history runs 6 years deep, the most recent figure standing at $273.2 million for Q1 2026.

• In Q1 2026, Common Equity rose 35.62% year-over-year to $273.2 million; the TTM figure through Mar 2026 stood at $273.2 million (up 35.62% YoY), while the FY2025 annual figure was $305.3 million, up 85.27% from the prior year.
• Common Equity was $273.2 million for Q1 2026 at Amylyx Pharmaceuticals, down from $305.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $433.4 million in Q4 2023 to a low of $144.0 million in Q3 2022.
• Historically, Common Equity has averaged $278.6 million across 5 years, with a median of $273.2 million in 2026.
• The sharpest annual moves came in 2022 and 2024: Common Equity soared 398.83% in 2022, then sank 61.99% in 2024.
• A 5-year view of Common Equity shows it stood at $340.6 million in 2022, then grew by 27.25% to $433.4 million in 2023, then tumbled by 61.99% to $164.8 million in 2024, then jumped by 85.27% to $305.3 million in 2025, then fell by 10.52% to $273.2 million in 2026.
• The last three Common Equity figures came in at $273.2 million (Q1 2026), $305.3 million (Q4 2025), and $332.0 million (Q3 2025), per Business Quant data.